Ellerson Group’s iShares Biotechnology ETF IBB Stock Holding History

Ellerson Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,059	Closed	-$130K	–	55
2023 Q3	$130K	Buy	+1,059	New	+$135K	0.12%	56

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ellerson Group's IBB Position: Q4 2023 in Review

Ellerson Group sold out of iShares Biotechnology ETF (IBB) in Q4 2023, closing a stake of 1,059 shares — an estimated $130K sold.

Ellerson Group first reported a position in IBB in Q3 2023 and held it in 1 quarter. The position peaked at $130K in Q3 2023. 872 funds tracked by Wall St. Rank hold IBB as of Q4 2023.

Ellerson Group reported no remaining iShares Biotechnology ETF position as of Q4 2023 after selling out during the quarter.
Ellerson Group sold 1,059 iShares Biotechnology ETF shares in Q4 2023, an estimated $130K.
Ellerson Group first reported a position in iShares Biotechnology ETF in Q3 2023 and held it in 1 quarter.
Ellerson Group's iShares Biotechnology ETF position peaked at $130K in Q3 2023.
872 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2023.

Based on Ellerson Group's 13F filing for Q4 2023, filed 6 Feb 2024.